Trial Profile
Phase I/IIa combination study of upamostat in cholangiocarcinoma
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 20 Mar 2020 New trial record
- 19 Mar 2020 According to a Heidelberg Pharma media release, the company will test upamostat as a third arm once an agreement with the FDA has been reached.